Artificial Intelligence Enhances Breast Cancer Detection in Screening Mammograms
Artificial intelligence shows promise in detecting one-third of interval breast cancers missed during screening, potentially reducing aggressive cancers diagnosed between exams.
A recent study published in the journal Radiology reveals that artificial intelligence (AI) can significantly improve the detection of interval breast cancers—those diagnosed between regular screening exams. The research indicates that AI algorithms have the potential to identify approximately one-third of these cases that are often missed during initial screening, potentially reducing the number of cancers diagnosed symptomatically later.
Interval breast cancers tend to have poorer outcomes because they are typically more aggressive and grow rapidly. Digital breast tomosynthesis (DBT), also known as 3D mammography, has improved visualization of breast tissue, making it easier to spot cancers obscured in dense tissue. However, despite its advanced imaging capabilities, some cancers remain undetected.
In the study, researchers retrospectively analyzed 224 interval cancers from a total of 1,376 cases. They employed a sophisticated AI algorithm (Lunit INSIGHT DBT v1.1.0.0) and found that it accurately localized 32.6% of these previously missed cancers. Notably, the cancers detected by AI were generally larger and more likely to involve lymph nodes, suggesting that AI might be especially effective at identifying more aggressive tumors.
The study highlights that AI's benefit extends beyond simple detection. It correctly localized cancer sites with high precision, emphasizing its role as a second reader in screening workflows. Dr. Manisha Bahl, a leading researcher, explained that this lesion-level accuracy offers a more realistic measure of AI's clinical performance compared to exam-level assessments.
This pioneering research suggests that integrating AI into screening processes could greatly enhance early detection, reduce interval cancer rates, and potentially save lives by catching cancers when they are more treatable. Nonetheless, further validation in diverse clinical settings is necessary to fully understand its impact on long-term outcomes.
Source: https://medicalxpress.com/news/2025-07-ai-interval-breast-cancers-screening.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding How SARS-CoV-2 Continues to Evolve: Insights from Long-Term Lab Research
Recent long-term studies reveal SARS-CoV-2's remarkable ability to mutate, with recurring changes that can predict future variants and inform vaccine development.
FDA Issues Warning to Companies Selling Unlawful Opioid Containing Products
The FDA has issued warnings to companies selling unapproved products containing 7-hydroxymitragynine, a compound found in kratom, citing safety and regulatory violations. Learn more about these enforcement actions aimed at consumer protection.
Emerging Public Health Threat: Rising Rates of Cardiovascular-Kidney-Metabolic Syndrome in the US
A new study shows a significant rise in cardiovascular-kidney-metabolic syndrome across the US, affecting 80% of the population and highlighting the urgent need for integrated prevention efforts.
The United States' Preparedness for Its Aging Population: Insights from Recent Research
Recent research reveals significant disparities in access to vital services for America's aging population and emphasizes the urgent need for infrastructure and policy improvements to meet future demands.